Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 9/20 | 0.59 |
| ▸ | BRAF | P15056 | 12/20 | 0.54 |
| ▸ | RAF1 | P04049 | 7/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.54 |
| ▸ | PLK4 | O00444 | 2/20 | 0.52 |
| ▸ | AURKA | O14965 | 2/20 | 0.52 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.52 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.52 |
| ▸ | ABL1 | P00519 | 2/20 | 0.52 |
| ▸ | LCK | P06239 | 2/20 | 0.52 |
| ▸ | FYN | P06241 | 2/20 | 0.52 |
| ▸ | LYN | P07948 | 2/20 | 0.52 |
| ▸ | RET | P07949 | 2/20 | 0.52 |
| ▸ | SRC | P12931 | 2/20 | 0.52 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.52 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.52 |
| ▸ | AXL | P30530 | 2/20 | 0.52 |
| ▸ | FRK | P42685 | 2/20 | 0.52 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.52 |
| ▸ | BLK | P51451 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6014811 | 0.88 | KDR (0.63) | KDRBRAFRAF1EPHX2PLK4 | |
| SCHEMBL8738426 | 0.84 | KDR (0.59) | KDRBRAFRAF1EPHX2PLK4 | |
| SCHEMBL12391452 | 0.84 | KDR (0.59) | KDRBRAFRAF1EPHX2PLK4 | |
| SCHEMBL6014190 | 0.84 | KDR (0.59) | KDRBRAFRAF1EPHX2PLK4 | |
| SCHEMBL12355381 | 0.84 | KDR (0.59) | KDRBRAFRAF1EPHX2PLK4 | |
| SCHEMBL167964 | 0.83 | KDR (0.68) | KDRBRAFRAF1EPHX2PLK4 | |
| SCHEMBL13648151 | 0.82 | KDR (0.57) | KDRBRAFRAF1EPHX2PLK4 | |
| SCHEMBL618015 | 0.82 | KDR (0.59) | KDRBRAFRAF1EPHX2PLK4 | |
| SCHEMBL14402761 | 0.81 | KDR (0.56) | KDRBRAFRAF1EPHX2PLK4 | |
| Hydrochloric Acid SCHEMBL621069 | 0.81 | KDR (0.58) | KDRBRAFRAF1EPHX2PLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190046650-A1 | CELLULAR SIGNALLING INHIBITORS, THEIR FORMULATIONS AND METHODS THEREOF | INVICTUS ONCOLOGY PVT. LTD. (IN) | 2019-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190046650-A1 | CELLULAR SIGNALLING INHIBITORS, THEIR FORMULATIONS AND METHODS THEREOF | CSF1R, CSF3R, MSR1 | KDR 1088/4885BRAF 355/4885RAF1 528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.